Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| Nanoparticles |
 |
 |
 |
|
Generation of re-dispersible nanoparticles is still a major challenge. Most available’ bottom-up’ techniques (like supercritical fluid antisolvent techniques) produce heavily agglomerated masses of particles which do not break up on re-constitution, while ‘top-down’ methods such as milling are time consuming and often generate a substantially broad size distribution. Additionally, high excipient loadings (e.g. 50-90 %) are frequently used with other technologies to ensure the generation of stable nanoparticles. The ASP Process (Atmospheric Supercritical Precipitation) is capable of producing nanoparticles with size ranges between 200-1000 nm which are easy to re-disperse in a suitable carrier. Excipients such as polymers, surfactants or pH-regulators can be added if necessary or desired. Produced nanoparticles are recovered as fine dry powder providing intimate contact between active and possible excipients. |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis